BioImpact Capital LLC is 10% Owner at iTeos Therapeutics, Inc. (ITOS). They have made 3 open-market trades across 1 company since 2021, most recently 2021-12-02.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITOS | SELL | 2021-11-30 | 2021-12-02 | $34.47 | $9.6M | +6.5% | +35.8% | +1.5% |
| ITOS | SELL | 2021-09-28 | 2021-09-30 | $27.00 | $972K | -1.2% | +3.2% | +70.8% |
| CGEM | SELL · 10b5-1 | 2021-09-16 | 2021-09-20 | $29.06 | $91K | -8.5% | -11.3% | -35.5% |
| CGEM | SELL · 10b5-1 | 2021-09-14 | 2021-09-16 | $29.17 | $207K | -20.9% | -26.8% | -44.8% |
| ITOS | SELL | 2021-09-09 | 2021-09-13 | $28.32 | $5.5M | +2.0% | -4.4% | +34.3% |
| CGEM | SELL · 10b5-1 | 2021-09-09 | 2021-09-13 | $29.23 | $680K | -18.0% | -19.7% | -44.1% |
| CGEM | SELL · 10b5-1 | 2021-09-03 | 2021-09-08 | $29.20 | $1.4M | -15.7% | -17.7% | -39.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.